DarioHealth Key Executives
This section highlights DarioHealth's key executives, including their titles and compensation details.
Find Contacts at DarioHealth
(Showing 0 of )
DarioHealth Earnings
This section highlights DarioHealth's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-10 | $-0.16 | $0.01 |
| Read Transcript | Q3 | 2024 | 2024-11-09 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-08-10 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-15 | $-0.59 | $-0.20 |
| Read Transcript | Q4 | 2023 | 2024-03-28 | $-0.54 | $-0.41 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $-0.50 | $-0.49 |
| Read Transcript | Q2 | 2023 | 2023-08-10 | $-0.52 | $-0.58 |
| Read Transcript | Q1 | 2023 | 2023-05-11 | $-0.46 | $0.45 |
Financial Statements
Access annual & quarterly financial statements for DarioHealth, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $27.04M | $20.35M | $27.66M | $20.51M | $7.58M |
| Cost of Revenue | $13.77M | $14.37M | $18.00M | $16.55M | $5.06M |
| Gross Profit | $13.27M | $5.98M | $9.65M | $3.96M | $2.51M |
| Gross Profit Ratio | 49.06% | 29.40% | 34.91% | 19.32% | 33.17% |
| Research and Development Expenses | $24.18M | $20.25M | $19.65M | $17.22M | $4.43M |
| General and Administrative Expenses | $20.48M | $18.01M | $16.49M | $23.53M | $12.76M |
| Selling and Marketing Expenses | $26.35M | $23.79M | $30.32M | $39.71M | $15.23M |
| Selling General and Administrative Expenses | $46.83M | $41.80M | $46.82M | $63.24M | $27.98M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $71.01M | $62.17M | $66.47M | $80.46M | $32.42M |
| Cost and Expenses | $84.78M | $76.41M | $84.47M | $97.01M | $37.48M |
| Interest Income | $- | $1.87M | $506.00K | $44.00K | $61.00K |
| Interest Expense | $- | $645.00K | $1.88M | $84.00K | $49.00K |
| Depreciation and Amortization | $- | $4.99M | $3.80M | $3.53M | $457.00K |
| EBITDA | $-57.74M | $-54.38M | $-56.81M | $-73.12M | $-29.71M |
| EBITDA Ratio | -213.55% | -267.19% | -205.42% | -356.44% | -392.20% |
| Operating Income | $-57.74M | $-56.19M | $-56.81M | $-76.49M | $-29.90M |
| Operating Income Ratio | -213.55% | -276.09% | -205.42% | -372.90% | -394.71% |
| Total Other Income Expenses Net | $98.73M | $-3.17M | $-5.38M | $-235.00K | $458.00K |
| Income Before Tax | $40.98M | $-59.36M | $-62.19M | $-76.73M | $-29.45M |
| Income Before Tax Ratio | 151.56% | -291.68% | -224.87% | -374.05% | -388.66% |
| Income Tax Expense | $40.98M | $64.00K | $4.00K | $32.00K | $-458.00K |
| Net Income | $40.98M | $-59.43M | $-62.19M | $-76.76M | $-28.99M |
| Net Income Ratio | 151.56% | -292.00% | -224.88% | -374.21% | -382.62% |
| EPS | $0.61 | $-1.93 | $-2.63 | $-4.63 | $-4.86 |
| EPS Diluted | $0.61 | $-1.93 | $-2.63 | $-4.63 | $-4.86 |
| Weighted Average Shares Outstanding | 67.18M | 28.37M | 23.64M | 16.59M | 5.96M |
| Weighted Average Shares Outstanding Diluted | 67.18M | 28.37M | 23.64M | 16.59M | 5.96M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.60M | $7.42M | $6.25M | $5.76M | $3.62M | $3.52M | $6.15M | $7.07M | $6.81M | $6.61M | $6.18M | $8.06M | $6.03M | $5.63M | $5.26M | $3.60M | $2.08M | $2.04M | $1.79M | $1.67M |
| Cost of Revenue | $3.40M | $3.55M | $3.50M | $3.33M | $3.48M | $2.91M | $4.08M | $3.90M | $4.08M | $4.80M | $5.04M | $4.07M | $5.48M | $4.80M | $3.75M | $2.51M | $1.53M | $1.49M | $1.15M | $888.00K |
| Gross Profit | $4.20M | $3.88M | $2.76M | $2.43M | $132.00K | $610.00K | $2.07M | $3.17M | $2.73M | $1.80M | $1.14M | $3.98M | $548.00K | $826.00K | $1.51M | $1.08M | $549.00K | $549.00K | $636.00K | $779.00K |
| Gross Profit Ratio | 55.26% | 52.23% | 44.06% | 42.24% | 3.65% | 17.34% | 33.71% | 44.83% | 40.12% | 27.25% | 18.41% | 49.45% | 9.09% | 14.67% | 28.66% | 30.07% | 26.39% | 26.89% | 35.59% | 46.73% |
| Research and Development Expenses | $5.28M | $5.45M | $6.81M | $6.64M | $4.20M | $5.67M | $5.22M | $5.17M | $4.78M | $4.80M | $4.14M | $5.93M | $5.32M | $5.51M | $3.74M | $2.65M | $1.42M | $954.00K | $825.00K | $1.23M |
| General and Administrative Expenses | $5.01M | $3.73M | $5.00M | $6.74M | $5.53M | $4.13M | $4.41M | $4.07M | $3.04M | $4.00M | $5.06M | $4.39M | $4.67M | $7.12M | $6.12M | $5.62M | $3.30M | $2.56M | $1.33M | $5.57M |
| Selling and Marketing Expenses | $5.58M | $6.73M | $7.13M | $6.91M | $4.62M | $6.36M | $6.46M | $6.34M | $3.92M | $7.57M | $9.30M | $9.54M | $12.23M | $10.70M | $9.65M | $7.13M | $4.89M | $3.63M | $2.61M | $4.09M |
| Selling General and Administrative Expenses | $10.59M | $10.46M | $12.02M | $13.05M | $10.02M | $10.49M | $10.87M | $10.41M | $6.96M | $11.57M | $14.36M | $13.93M | $16.90M | $17.82M | $15.77M | $12.75M | $8.19M | $6.20M | $3.93M | $9.66M |
| Other Expenses | $92.15M | $-24.06M | $-31.15M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $17.82M | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $108.02M | $-8.15M | $18.83M | $19.69M | $14.22M | $16.16M | $16.09M | $15.58M | $11.74M | $16.37M | $18.49M | $19.86M | $22.21M | $23.32M | $19.51M | $15.41M | $9.61M | $7.15M | $4.76M | $10.89M |
| Cost and Expenses | $111.42M | $-4.61M | $22.33M | $23.02M | $17.70M | $19.06M | $20.17M | $19.47M | $15.82M | $21.18M | $23.54M | $23.93M | $27.69M | $28.13M | $23.26M | $17.92M | $11.14M | $8.64M | $5.91M | $11.78M |
| Interest Income | $161.00K | $- | $- | $390.00K | $470.00K | $534.00K | $529.00K | $335.00K | $278.00K | $198.00K | $- | $4.00K | $8.00K | $- | $- | $9.00K | $- | $- | $- | $35.00K |
| Interest Expense | $-3.26M | $- | $- | $920.00K | $557.00K | $23.00K | $16.00K | $1.07M | $907.00K | $- | $- | $26.00K | $24.00K | $- | $- | $43.00K | $- | $- | $- | $36.00K |
| Depreciation and Amortization | $2.13M | $2.13M | $1.84M | $1.48M | $1.33M | $1.33M | $1.32M | $1.25M | $1.25M | $1.23M | $1.28M | $1.04M | $793.00K | $1.43M | $859.00K | $445.00K | $50.00K | $48.00K | $46.00K | $46.00K |
| EBITDA | $-9.53M | $-9.90M | $-14.35M | $-16.53M | $-12.33M | $-14.38M | $-12.80M | $-11.20M | $-10.43M | $-13.35M | $-16.15M | $-14.85M | $-20.74M | $-21.01M | $-16.89M | $-13.89M | $-9.01M | $-6.55M | $-4.08M | $-10.07M |
| EBITDA Ratio | -125.37% | -133.40% | -229.46% | -287.06% | -341.07% | -408.75% | -208.08% | -158.49% | -153.22% | -202.07% | -261.15% | -184.27% | -344.01% | -373.23% | -321.10% | -386.31% | -433.37% | -320.96% | -228.15% | -603.96% |
| Operating Income | $-103.82M | $-12.03M | $-16.07M | $-17.26M | $-14.09M | $-15.55M | $-14.02M | $-12.41M | $-9.01M | $-14.57M | $-17.36M | $-15.87M | $-21.66M | $-22.50M | $-18.00M | $-14.33M | $-9.06M | $-6.60M | $-4.12M | $-10.11M |
| Operating Income Ratio | -1365.33% | -162.06% | -256.93% | -299.79% | -389.57% | -441.90% | -227.89% | -175.60% | -132.32% | -220.64% | -280.69% | -196.95% | -359.41% | -399.70% | -342.20% | -398.53% | -435.77% | -323.31% | -230.72% | -606.72% |
| Total Other Income Expenses Net | $94.34M | $26.64M | $2.58M | $8.09M | $-28.44M | $-186.00K | $-2.56M | $-417.00K | $-3.60M | $-1.06M | $-672.00K | $-44.00K | $111.00K | $55.00K | $238.00K | $-639.00K | $67.00K | $52.00K | $117.00K | $222.00K |
| Income Before Tax | $-9.48M | $14.61M | $-13.61M | $-9.17M | $-14.22M | $16.90M | $-16.59M | $-12.82M | $-12.61M | $-15.63M | $-18.03M | $-15.92M | $-21.55M | $-22.44M | $-17.77M | $-14.97M | $-9.00M | $-6.55M | $-4.01M | $-9.89M |
| Income Before Tax Ratio | -124.63% | 196.79% | -217.59% | -159.24% | -393.28% | 480.50% | -269.59% | -181.50% | -185.25% | -236.67% | -291.56% | -197.49% | -357.56% | -398.72% | -337.67% | -416.30% | -432.55% | -320.76% | -224.17% | -593.40% |
| Income Tax Expense | $155.00K | $-13.00K | $-10.24M | $-1.99M | $64.00K | $-1.24M | $34.86M | $-25.23M | $3.00K | $1.06M | $1.00K | $44.00K | $32.00K | $-488.00K | $-59.00K | $639.00K | $- | $- | $- | $-222.00K |
| Net Income | $-9.63M | $-12.33M | $-3.37M | $-6.92M | $-12.00M | $16.90M | $-16.59M | $12.41M | $-12.62M | $-16.69M | $-18.03M | $-15.96M | $-21.59M | $-22.44M | $-17.77M | $-14.97M | $-9.00M | $-6.55M | $-4.01M | $-9.89M |
| Net Income Ratio | -126.67% | -166.11% | -53.86% | -120.13% | -331.88% | 480.50% | -269.59% | 175.60% | -185.30% | -252.70% | -291.57% | -198.04% | -358.10% | -398.72% | -337.67% | -416.30% | -432.55% | -320.76% | -224.17% | -593.40% |
| EPS | $0.36 | $0.36 | $-0.08 | $-0.20 | $-0.44 | $0.59 | $-0.59 | $0.45 | $-0.49 | $-0.73 | $-0.80 | $-0.81 | $-1.38 | $-1.36 | $-1.13 | $-1.07 | $-1.23 | $-0.89 | $-0.97 | $-3.20 |
| EPS Diluted | $0.36 | $0.36 | $-0.08 | $-0.20 | $-0.44 | $0.59 | $-0.59 | $0.45 | $-0.49 | $-0.73 | $-0.80 | $-0.81 | $-1.38 | $-1.36 | $-1.13 | $-1.07 | $-1.23 | $-0.89 | $-0.97 | $-3.20 |
| Weighted Average Shares Outstanding | 40.42M | 40.42M | 39.83M | 34.44M | 27.19M | 28.82M | 28.19M | 27.57M | 25.72M | 22.87M | 22.43M | 19.62M | 15.69M | 16.47M | 15.69M | 14.03M | 7.33M | 7.33M | 4.12M | 3.09M |
| Weighted Average Shares Outstanding Diluted | 40.42M | 40.42M | 39.83M | 34.44M | 27.19M | 28.82M | 28.19M | 27.57M | 25.72M | 22.97M | 22.43M | 19.62M | 15.69M | 16.47M | 15.69M | 14.03M | 7.33M | 7.33M | 4.12M | 3.09M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $27.76M | $36.80M | $49.36M | $35.81M | $28.59M |
| Short Term Investments | $697.00K | $- | $- | $- | $- |
| Cash and Short Term Investments | $28.46M | $36.80M | $49.36M | $35.81M | $28.59M |
| Net Receivables | $- | $3.64M | $6.42M | $1.79M | $1.70M |
| Inventory | $- | $5.06M | $7.96M | $6.23M | $2.29M |
| Other Current Assets | $175.00K | $1.83M | $1.79M | $1.78M | $1.54M |
| Total Current Assets | $28.64M | $47.33M | $65.52M | $45.60M | $34.13M |
| Property Plant Equipment Net | $1.77M | $1.87M | $1.99M | $989.00K | $1.07M |
| Goodwill | $57.43M | $41.64M | $41.64M | $41.64M | $- |
| Intangible Assets | $18.76M | $5.40M | $9.92M | $12.46M | $- |
| Goodwill and Intangible Assets | $76.19M | $47.04M | $51.56M | $54.10M | $- |
| Long Term Investments | $- | $- | $6.00K | $20.00K | $20.00K |
| Tax Assets | $- | $- | $-6.00K | $-20.00K | $- |
| Other Non-Current Assets | $392.00K | $149.00K | $117.00K | $77.00K | $185.00K |
| Total Non-Current Assets | $78.36M | $49.06M | $53.67M | $55.17M | $1.28M |
| Other Assets | $11.89M | $- | $- | $- | $- |
| Total Assets | $118.88M | $96.39M | $119.19M | $100.77M | $35.41M |
| Account Payables | $3.04M | $1.13M | $2.32M | $5.11M | $2.48M |
| Short Term Debt | $5.96M | $4.07M | $9.12M | $532.00K | $620.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $1.58M | $997.00K | $1.32M | $1.20M | $1.22M |
| Other Current Liabilities | $6.05M | $6.30M | $6.59M | $7.54M | $2.71M |
| Total Current Liabilities | $16.64M | $12.49M | $19.35M | $14.38M | $7.03M |
| Long Term Debt | $24.24M | $25.48M | $18.93M | $21.00K | $222.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $5.99M | $276.00K | $910.00K | $825.00K | $- |
| Total Non-Current Liabilities | $30.23M | $25.75M | $19.84M | $846.00K | $222.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $46.87M | $38.24M | $39.19M | $15.22M | $7.26M |
| Preferred Stock | $- | $- | $- | $1 | $- |
| Common Stock | $4.00K | $3.00K | $3.00K | $2.00K | $- |
| Retained Earnings | $-390.34M | $-349.36M | $-285.85M | $-222.01M | $-143.25M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $0 | $- |
| Other Total Stockholders Equity | $462.36M | $407.50M | $365.85M | $307.56M | $171.40M |
| Total Stockholders Equity | $72.02M | $58.14M | $80.00M | $85.55M | $28.15M |
| Total Equity | $72.02M | $58.14M | $80.00M | $85.55M | $28.15M |
| Total Liabilities and Stockholders Equity | $118.88M | $96.39M | $119.19M | $100.77M | $35.41M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $118.88M | $96.39M | $119.19M | $100.77M | $35.41M |
| Total Investments | $697.00K | $6.00K | $6.00K | $20.00K | $20.00K |
| Total Debt | $30.19M | $29.54M | $28.05M | $287.00K | $532.00K |
| Net Debt | $2.43M | $-7.26M | $-21.31M | $-35.52M | $-28.06M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $27.76M | $15.55M | $23.80M | $35.34M | $37.09M | $43.88M | $52.60M | $38.79M | $49.36M | $57.08M | $67.95M | $55.56M | $35.81M | $51.33M | $63.87M | $81.17M | $28.59M | $36.91M | $13.18M | $15.83M |
| Short Term Investments | $697.00K | $- | $- | $- | $- | $- | $- | $4.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $28.46M | $15.55M | $23.80M | $35.34M | $37.09M | $43.88M | $52.60M | $43.09M | $49.36M | $57.08M | $67.95M | $55.56M | $35.81M | $51.33M | $63.87M | $81.17M | $28.59M | $36.91M | $13.18M | $15.83M |
| Net Receivables | $5.35M | $8.38M | $6.73M | $7.88M | $3.15M | $4.53M | $4.82M | $2.80M | $6.42M | $4.52M | $3.14M | $4.57M | $1.79M | $2.11M | $1.43M | $468.00K | $1.70M | $543.00K | $624.00K | $774.00K |
| Inventory | $4.75M | $4.74M | $5.13M | $4.92M | $5.06M | $5.47M | $5.91M | $6.88M | $7.96M | $7.76M | $8.35M | $7.78M | $6.23M | $4.06M | $4.58M | $5.02M | $2.29M | $1.57M | $1.34M | $1.22M |
| Other Current Assets | $1.96M | $863.00K | $4.54M | $5.34M | $2.32M | $2.33M | $2.44M | $2.71M | $1.79M | $2.22M | $3.01M | $3.46M | $1.78M | $1.73M | $1.74M | $1.60M | $1.54M | $808.00K | $660.00K | $672.00K |
| Total Current Assets | $40.53M | $29.53M | $39.34M | $52.51M | $47.09M | $56.21M | $65.78M | $55.48M | $65.52M | $71.58M | $82.44M | $71.38M | $45.60M | $59.23M | $71.61M | $88.26M | $34.13M | $39.83M | $15.81M | $18.49M |
| Property Plant Equipment Net | $1.77M | $2.54M | $2.88M | $3.24M | $1.87M | $1.98M | $1.89M | $1.94M | $1.99M | $2.03M | $985.00K | $978.00K | $989.00K | $1.07M | $1.12M | $1.21M | $1.07M | $1.12M | $1.20M | $1.31M |
| Goodwill | $57.43M | $57.43M | $57.43M | $57.43M | $41.64M | $41.64M | $41.64M | $41.64M | $41.64M | $41.64M | $41.64M | $41.64M | $41.64M | $39.40M | $39.40M | $25.33M | $- | $- | $- | $- |
| Intangible Assets | $18.76M | $20.34M | $22.35M | $23.65M | $5.40M | $6.54M | $7.68M | $8.80M | $9.92M | $11.05M | $12.19M | $13.31M | $12.46M | $17.41M | $18.70M | $9.22M | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $76.19M | $77.77M | $79.77M | $81.07M | $47.04M | $48.18M | $49.32M | $50.44M | $51.56M | $52.69M | $53.83M | $54.95M | $54.10M | $56.81M | $58.10M | $34.56M | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $6.00K | $6.00K | $6.00K | $5.00K | $6.00K | $6.00K | $6.00K | $6.00K | $9.00K | $7.00K | $20.00K | $20.00K | $20.00K | $20.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $23.65M | $5.40M | $-5.00K | $-6.00K | $-6.00K | $-6.00K | $-6.00K | $-9.00K | $-7.00K | $-20.00K | $-20.00K | $-20.00K | $-20.00K | $- | $- | $- | $- |
| Other Non-Current Assets | $392.00K | $114.00K | $134.00K | $-23.51M | $-5.02M | $136.00K | $176.00K | $155.00K | $117.00K | $27.00K | $71.00K | $23.00K | $77.00K | $77.00K | $157.00K | $158.00K | $205.00K | $196.00K | $200.00K | $226.00K |
| Total Non-Current Assets | $78.36M | $80.42M | $82.79M | $84.45M | $49.30M | $50.29M | $51.38M | $52.53M | $53.67M | $54.75M | $54.90M | $55.95M | $55.17M | $57.96M | $59.37M | $35.93M | $1.28M | $1.31M | $1.40M | $1.54M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $118.88M | $109.95M | $122.13M | $136.96M | $96.39M | $106.50M | $117.16M | $108.01M | $119.19M | $126.33M | $137.34M | $127.33M | $100.77M | $117.19M | $130.98M | $124.19M | $35.41M | $41.14M | $17.21M | $20.03M |
| Account Payables | $3.04M | $2.65M | $3.35M | $4.25M | $1.13M | $1.93M | $1.45M | $1.88M | $2.32M | $1.98M | $3.28M | $4.23M | $5.11M | $3.99M | $4.04M | $3.43M | $2.48M | $2.00M | $1.58M | $1.24M |
| Short Term Debt | $5.96M | $9.27M | $6.96M | $4.87M | $4.18M | $238.00K | $290.00K | $8.87M | $9.12M | $540.00K | $274.00K | $424.00K | $266.00K | $586.00K | $622.00K | $642.00K | $310.00K | $570.00K | $574.00K | $586.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $1.58M | $1.12M | $1.51M | $1.79M | $997.00K | $684.00K | $789.00K | $925.00K | $1.32M | $990.00K | $999.00K | $1.09M | $1.20M | $1.21M | $1.31M | $1.39M | $1.22M | $1.28M | $1.27M | $1.26M |
| Other Current Liabilities | $6.05M | $5.81M | $5.59M | $6.89M | $6.19M | $9.83M | $10.30M | $5.93M | $6.59M | $7.74M | $14.10M | $7.14M | $7.81M | $12.57M | $12.23M | $11.19M | $3.02M | $2.00M | $1.24M | $1.14M |
| Total Current Liabilities | $16.64M | $18.85M | $17.42M | $17.80M | $12.49M | $8.11M | $8.08M | $17.62M | $19.35M | $11.52M | $12.99M | $13.10M | $14.38M | $12.68M | $12.74M | $11.74M | $7.03M | $5.85M | $4.66M | $4.23M |
| Long Term Debt | $24.24M | $21.22M | $24.56M | $25.56M | $25.48M | $29.80M | $29.98M | $17.50M | $18.93M | $24.86M | $23.11M | $48.00K | $21.00K | $66.00K | $125.00K | $178.00K | $222.00K | $258.00K | $319.00K | $378.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $5.99M | $11.38M | $12.11M | $15.57M | $276.00K | $560.00K | $700.00K | $866.00K | $910.00K | $1.00M | $1.59M | $- | $825.00K | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $30.23M | $32.60M | $36.66M | $41.13M | $25.75M | $30.36M | $30.68M | $18.36M | $19.84M | $25.86M | $24.70M | $48.00K | $846.00K | $66.00K | $125.00K | $178.00K | $222.00K | $258.00K | $319.00K | $378.00K |
| Other Liabilities | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $46.87M | $51.44M | $54.08M | $58.93M | $38.24M | $38.47M | $38.76M | $35.98M | $39.19M | $37.39M | $37.69M | $13.15M | $15.22M | $12.75M | $12.87M | $11.92M | $7.26M | $6.11M | $4.98M | $4.61M |
| Preferred Stock | $- | $- | $- | $0 | $- | $- | $1 | $- | $- | $1 | $- | $0 | $1 | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K | $2.00K | $2.00K | $2.00K | $- | $- | $- | $- | $- | $- | $- |
| Retained Earnings | $-390.34M | $-378.08M | $-363.47M | $-358.57M | $-349.36M | $-333.86M | $-316.95M | $-298.68M | $-285.85M | $-272.97M | $-256.84M | $-238.38M | $-222.01M | $-199.94M | $-177.01M | $-158.76M | $-143.25M | $-133.58M | $-126.10M | $-121.31M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-0 | $- | $- | $0 | $- | $- | $0 | $- | $-0 | $0 | $- | $-0 | $0 | $- | $- | $-0 | $- |
| Other Total Stockholders Equity | $462.36M | $436.59M | $431.53M | $436.60M | $407.50M | $401.89M | $395.35M | $370.70M | $365.85M | $361.91M | $356.49M | $352.56M | $307.56M | $304.38M | $295.12M | $271.02M | $171.40M | $168.62M | $138.33M | $136.74M |
| Total Stockholders Equity | $72.02M | $58.51M | $68.06M | $78.03M | $58.14M | $68.03M | $78.40M | $72.03M | $80.00M | $88.95M | $99.65M | $114.19M | $85.55M | $104.44M | $118.11M | $112.27M | $28.15M | $35.03M | $12.23M | $15.43M |
| Total Equity | $72.02M | $58.51M | $68.06M | $78.03M | $58.14M | $68.03M | $78.40M | $72.03M | $80.00M | $88.95M | $99.65M | $114.19M | $85.55M | $104.44M | $118.11M | $112.27M | $28.15M | $35.03M | $12.23M | $15.43M |
| Total Liabilities and Stockholders Equity | $118.88M | $109.95M | $122.13M | $136.96M | $96.39M | $106.50M | $117.16M | $108.01M | $119.19M | $126.33M | $137.34M | $127.33M | $100.77M | $117.19M | $130.98M | $124.19M | $35.41M | $41.14M | $17.21M | $20.03M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $118.88M | $109.95M | $122.13M | $136.96M | $96.39M | $106.50M | $117.16M | $108.01M | $119.19M | $126.33M | $137.34M | $127.33M | $100.77M | $117.19M | $130.98M | $124.19M | $35.41M | $41.14M | $17.21M | $20.03M |
| Total Investments | $697.00K | $- | $6.00K | $6.00K | $6.00K | $5.00K | $6.00K | $4.30M | $6.00K | $6.00K | $9.00K | $7.00K | $20.00K | $20.00K | $20.00K | $20.00K | $- | $- | $- | $- |
| Total Debt | $30.19M | $30.49M | $30.63M | $30.43M | $29.54M | $29.92M | $30.12M | $26.37M | $28.05M | $25.13M | $23.25M | $260.00K | $287.00K | $359.00K | $436.00K | $499.00K | $532.00K | $543.00K | $606.00K | $671.00K |
| Net Debt | $2.43M | $14.94M | $6.84M | $-4.90M | $-7.55M | $-13.96M | $-22.48M | $-12.42M | $-21.31M | $-31.95M | $-44.70M | $-55.30M | $-35.52M | $-50.97M | $-63.43M | $-80.67M | $-28.06M | $-36.36M | $-12.58M | $-15.15M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-42.75M | $-59.43M | $-62.19M | $-76.76M | $-29.45M |
| Depreciation and Amortization | $7.43M | $4.99M | $4.72M | $3.32M | $190.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-12.68M |
| Stock Based Compensation | $15.80M | $19.70M | $16.98M | $24.97M | $11.10M |
| Change in Working Capital | $-2.47M | $4.07M | $-10.90M | $-2.57M | $417.00K |
| Accounts Receivables | $1.60M | $2.83M | $-5.11M | $-351.00K | $548.00K |
| Inventory | $308.00K | $2.89M | $-1.73M | $-2.23M | $-879.00K |
| Accounts Payables | $-3.48M | $-1.19M | $-2.79M | $1.08M | $824.00K |
| Other Working Capital | $-895.00K | $-464.00K | $-1.28M | $-1.07M | $-76.00K |
| Other Non Cash Items | $-16.57M | $288.00K | $3.56M | $637.00K | $12.68M |
| Net Cash Provided by Operating Activities | $-38.56M | $-30.38M | $-47.84M | $-50.41M | $-17.74M |
| Investments in Property Plant and Equipment | $-138.00K | $-584.00K | $-573.00K | $-261.00K | $-118.00K |
| Acquisitions Net | $-8.80M | $- | $- | $-7.47M | $- |
| Purchases of Investments | $- | $-5.00M | $- | $- | $-4.00K |
| Sales Maturities of Investments | $- | $5.03M | $- | $- | $- |
| Other Investing Activities | $- | $- | $-131.00K | $-400.00K | $-1.50M |
| Net Cash Used for Investing Activities | $-8.93M | $-547.00K | $-573.00K | $-8.13M | $-1.62M |
| Debt Repayment | $- | $1.77M | $23.79M | $- | $- |
| Common Stock Issued | $38.53M | $1.61M | $38.29M | $64.88M | $27.55M |
| Common Stock Repurchased | $- | $- | $-134.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $38.53M | $14.87M | $- | $889.00K | $- |
| Net Cash Used Provided by Financing Activities | $38.53M | $18.25M | $61.94M | $65.77M | $27.55M |
| Effect of Forex Changes on Cash | $-68.00K | $- | $- | $- | $- |
| Net Change in Cash | $-9.03M | $-12.67M | $13.52M | $7.22M | $8.19M |
| Cash at End of Period | $27.76M | $36.80M | $49.47M | $35.95M | $28.73M |
| Cash at Beginning of Period | $36.80M | $49.47M | $35.95M | $28.73M | $20.54M |
| Operating Cash Flow | $-38.56M | $-30.38M | $-47.84M | $-50.41M | $-17.74M |
| Capital Expenditure | $-138.00K | $-584.00K | $-573.00K | $-261.00K | $-118.00K |
| Free Cash Flow | $-38.70M | $-30.96M | $-48.42M | $-50.67M | $-17.85M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-9.63M | $-22.83M | $-3.37M | $-6.92M | $-12.00M | $-15.73M | $-16.59M | $-12.82M | $-12.62M | $-15.63M | $-18.03M | $-15.92M | $-21.59M | $-22.44M | $-17.77M | $-14.97M | $-9.00M | $-6.55M | $-4.01M | $-9.89M |
| Depreciation and Amortization | $2.13M | $1.98M | $1.84M | $1.48M | $1.33M | $1.24M | $1.22M | $1.21M | $1.25M | $1.23M | $1.21M | $1.03M | $719.00K | $1.36M | $800.00K | $439.00K | $50.00K | $48.00K | $46.00K | $46.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-6.17M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-417.00K | $- | $- | $- |
| Stock Based Compensation | $2.59M | $2.79M | $3.56M | $6.86M | $4.39M | $5.16M | $5.29M | $4.86M | $3.08M | $4.93M | $3.63M | $5.34M | $6.30M | $8.77M | $5.46M | $4.44M | $2.11M | $1.81M | $822.00K | $6.36M |
| Change in Working Capital | $1.90M | $17.70M | $-3.43M | $-14.27M | $1.46M | $926.00K | $-1.37M | $2.31M | $-1.45M | $-1.77M | $429.00K | $-8.10M | $-222.00K | $-582.00K | $-1.18M | $-594.00K | $73.00K | $900.00K | $499.00K | $-1.05M |
| Accounts Receivables | $958.00K | $2.06M | $1.85M | $-3.27M | $1.28M | $288.00K | $-2.02M | $3.62M | $-1.90M | $-1.38M | $1.44M | $-3.26M | $774.00K | $-673.00K | $-770.00K | $318.00K | $757.00K | $-60.00K | $180.00K | $-329.00K |
| Inventory | $-12.00K | $391.00K | $-217.00K | $146.00K | $409.00K | $443.00K | $963.00K | $1.08M | $-194.00K | $585.00K | $-564.00K | $-1.55M | $-2.33M | $55.00K | $73.00K | $-32.00K | $-721.00K | $-231.00K | $-120.00K | $193.00K |
| Accounts Payables | $390.00K | $-696.00K | $-898.00K | $708.00K | $-798.00K | $478.00K | $-432.00K | $-439.00K | $349.00K | $-1.30M | $-948.00K | $-890.00K | $1.08M | $-54.00K | $598.00K | $-544.00K | $481.00K | $420.00K | $340.00K | $-417.00K |
| Other Working Capital | $568.00K | $15.94M | $-4.16M | $-11.86M | $572.00K | $-283.00K | $123.00K | $-1.95M | $286.00K | $324.00K | $-94.00K | $-2.39M | $250.00K | $90.00K | $-1.08M | $-336.00K | $-444.00K | $771.00K | $99.00K | $-502.00K |
| Other Non Cash Items | $-3.73M | $-6.99M | $-3.46M | $11.96M | $3.64M | $-234.00K | $1.81M | $-307.00K | $1.80M | $557.00K | $1.65M | $-452.00K | $-348.00K | $462.00K | $372.00K | $151.00K | $417.00K | $435.00K | $345.00K | $-375.00K |
| Net Cash Provided by Operating Activities | $-6.73M | $-7.36M | $-11.36M | $-13.11M | $-7.34M | $-8.64M | $-9.64M | $-4.76M | $-7.94M | $-10.70M | $-11.12M | $-18.09M | $-15.14M | $-12.44M | $-12.31M | $-10.53M | $-6.76M | $-3.79M | $-2.64M | $-4.54M |
| Investments in Property Plant and Equipment | $-21.00K | $-32.00K | $-29.00K | $-56.00K | $-83.00K | $-281.00K | $-146.00K | $-74.00K | $-59.00K | $-174.00K | $-159.00K | $-181.00K | $-68.00K | $-96.00K | $-29.00K | $-68.00K | $-49.00K | $-28.00K | $-13.00K | $-28.00K |
| Acquisitions Net | $- | $- | $- | $-8.80M | $-4.29M | $- | $- | $4.29M | $- | $115.00K | $- | $- | $22.00K | $- | $-5.02M | $-2.47M | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $-5.00M | $- | $- | $- | $- | $2.00K | $-1.00K | $-1.00K | $- | $2.00K | $-2.00K | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $4.33M | $708.00K | $- | $- | $- | $- | $-25.00K | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $4.29M | $- | $4.33M | $-4.29M | $-16.00K | $- | $- | $-115.00K | $-375.00K | $-1.00K | $-1.00K | $-3.02M | $-1.50M | $-2.00K | $-2.00K | $- |
| Net Cash Used for Investing Activities | $-21.00K | $-32.00K | $-29.00K | $-8.85M | $-83.00K | $-281.00K | $4.18M | $-4.36M | $-59.00K | $-174.00K | $-159.00K | $-181.00K | $-444.00K | $-97.00K | $-5.05M | $-2.54M | $-1.55M | $-30.00K | $-15.00K | $-28.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $3.16M | $-1.39M | $- | $- | $23.79M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $20.21M | $- | $204.00K | $1.41M | $- | $265.00K | $- | $- | $38.02M | $-64.88M | $- | $55.00K | $64.88M | $- | $27.55M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-134.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $18.32M | $-20.21M | $- | $20.21M | $-26.65M | $- | $14.87M | $- | $- | $- | $- | $- | $- | $- | $55.00K | $834.00K | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $18.32M | $- | $- | $20.21M | $- | $204.00K | $19.44M | $-1.39M | $265.00K | $- | $23.65M | $38.02M | $-65.77M | $- | $55.00K | $65.71M | $- | $27.55M | $- | $- |
| Effect of Forex Changes on Cash | $-18.00K | $-2.00K | $-48.00K | $- | $30.19M | $-1.90M | $-28.30M | $- | $- | $- | $- | $- | $65.77M | $-65.77M | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $11.55M | $-7.59M | $-11.54M | $-1.75M | $-7.18M | $-8.72M | $13.98M | $-10.51M | $-7.74M | $-10.87M | $12.38M | $19.75M | $-15.58M | $-12.53M | $-17.30M | $52.64M | $-8.31M | $23.73M | $-2.65M | $-4.57M |
| Cash at End of Period | $27.76M | $16.21M | $23.80M | $35.34M | $37.09M | $44.22M | $52.94M | $38.96M | $49.47M | $57.20M | $68.07M | $55.70M | $35.95M | $51.53M | $64.06M | $81.36M | $28.73M | $37.03M | $13.31M | $15.96M |
| Cash at Beginning of Period | $16.21M | $23.80M | $35.34M | $37.09M | $44.27M | $52.94M | $38.96M | $49.47M | $57.20M | $68.07M | $55.70M | $35.95M | $51.53M | $64.06M | $81.36M | $28.73M | $37.03M | $13.31M | $15.96M | $20.54M |
| Operating Cash Flow | $-6.73M | $-7.36M | $-11.36M | $-13.11M | $-7.34M | $-8.64M | $-9.64M | $-4.76M | $-7.94M | $-10.70M | $-11.12M | $-18.09M | $-15.14M | $-12.44M | $-12.31M | $-10.53M | $-6.76M | $-3.79M | $-2.64M | $-4.54M |
| Capital Expenditure | $-21.00K | $-32.00K | $-29.00K | $-56.00K | $-83.00K | $-281.00K | $-146.00K | $-74.00K | $-59.00K | $-174.00K | $-159.00K | $-181.00K | $-68.00K | $-96.00K | $-29.00K | $-68.00K | $-49.00K | $-28.00K | $-13.00K | $-28.00K |
| Free Cash Flow | $-6.75M | $-7.39M | $-11.39M | $-13.17M | $-7.42M | $-8.93M | $-9.78M | $-4.83M | $-8.00M | $-10.87M | $-11.27M | $-18.27M | $-15.20M | $-12.53M | $-12.34M | $-10.60M | $-6.81M | $-3.82M | $-2.65M | $-4.57M |
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
$0.71
Stock Price
$29.60M
Market Cap
196
Employees
New York, NY
Location
Revenue (FY 2024)
$27.04M
32.9% YoY
Net Income (FY 2024)
$40.98M
169.0% YoY
EPS (FY 2024)
$0.61
131.6% YoY
Free Cash Flow (FY 2024)
$-38.70M
-25.0% YoY
Profitability
Gross Margin
49.1%
Net Margin
151.6%
ROE
56.9%
ROA
34.5%
Valuation
P/E Ratio
1.29
P/S Ratio
1.95
EV/EBITDA
-0.96
Market Cap
$29.60M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-38.56M
-26.9% YoY
Free Cash Flow
$-38.70M
-25.0% YoY
Balance Sheet Summary
Total Assets
$118.88M
23.3% YoY
Total Debt
$30.19M
2.2% YoY
Shareholder Equity
$72.02M
-47.7% YoY
Dividend Overview
No Dividend Data
DarioHealth Corp. doesn't currently pay dividends.
DarioHealth Dividends
Explore DarioHealth's dividend history, including dividend yield, payout ratio, and historical payments.
DarioHealth News
Read the latest news about DarioHealth, including recent articles, headlines, and updates.
DarioHealth Announces CFO Transition
NEW YORK , April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David , Chief Financial Officer, will retire from his role, effective May 15, 2025 . The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr.
DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers
Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025 NEW YORK , April 17, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1 support program and full AI-driven digital health suite to employers, with initial clients already implemented and contributing to revenue since January 2025. This marks Dario's first national benefit administrator partnership and represents a strategic step toward broader adoption across benefit administration channels.
Top U.S. Healthcare Institution Deploys DarioHealth's Full Suite, Contributing to 2025 Revenue Growth and Market Expansion
Second major healthcare employer signs with DarioHealth, accelerating growth in 2025 and reinforcing its leadership in AI-powered, clinically validated digital health solutions for chronic condition management NEW YORK , April 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer partnership with one of the nation's most respected research and medical institutions. The signed agreement is already live and generating recurring revenue in 2025, marking a significant milestone in Dario's ongoing expansion among innovation-driven employers seeking measurable health outcomes and ROI.
Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth
NEW YORK--(BUSINESS WIRE)--Market News Alerts Reports: DarioHealth Corp. (Nasdaq: DRIO)* emerges as a potential hidden gem in digital health as competitor Hinge Health prepares to go public at a multi-billion-dollar valuation, highlighting a dramatic valuation gap that savvy investors are beginning to notice. With Hinge Health filing for a potential April IPO at a valuation that according to recent reports could reach $3-6 billion despite recent market volatility, DarioHealth's comprehensive AI.
DarioHealth Corp. (DRIO) Q4 2024 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Conference Call Participants Charles Rhyee - TD Cowen Ashok Kumar - ThinkEquity David Grossman - Stifel Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Fourth Quarter 2024 Results Conference Call. At this time, all lines are in listen-only mode.
Market News Alert: DarioHealth Beats Q4 Expectations, Reports 398% Growth in B2B Recurring Revenue
NEW YORK--(BUSINESS WIRE)---- $DRIO #Biotech--Market News Alerts Updates: Market News Alerts Reports: DarioHealth Corp. (Nasdaq: DRIO) reported fourth quarter revenue of $7.6 million, beating analyst consensus of $7.39 million. B2B2C recurring revenue surged 398% year-over-year to $5.6 million in Q4, driven by rapid employer and health plan adoption of the company's comprehensive chronic care platform. Gross margins in the B2B2C business exceeded 80% over the past three quarters. Full-year 2024 revenue reached $2.
DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results
Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023. Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by 300% year over year as core business continues to gain traction.
Dario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula
The strategic arrangement fuels Dario's B2B2C sales growth, expanding access to over 15,000 providers nationwide NEW YORK , March 7, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a strategic collaboration with Rula Health, a leading provider of high-quality behavioral health services, to expand access to mental health support for employers and their workforce nationwide. Through this strategic collaboration, Dario clients will have access to Rula's extensive network of over 15,000 providers across the country with coverage of over 120 million commercial lives through most major insurance networks.
Dario Signs First Healthcare System as Employer Contract, Expanding Market Presence and Recurring Revenue Growth
Healthcare system collaborates with Dario to offer AI-powered chronic care management solutions as a benefit for their employee base of healthcare workers, expected to contribute to the current total of 15 new client signings in 2025, representing a significant head start in its 2025 net new client goal. NEW YORK , March 5, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of a contract with a major healthcare system to be added to its employer book of business, set to go live in the first quarter of 2025.
DarioHealth to Report Fourth Quarter and Full Year 2024 Results on Monday, March 10, 2025
Company to host conference call and webcast at 8:30am Eastern Time NEW YORK , March 4, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31 st, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Monday, March 10 th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.
DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors
Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK , Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B.
Market News Alert: DarioHealth Secures Significant New Agreement, Expanding Growth in the $1.2 Trillion Dollar Cardiometabolic Market
NEW YORK--(BUSINESS WIRE)---- $DRIO #AI--Market News Alerts Updates: DarioHealth Corp. (Nasdaq: DRIO)* has announced a significant new agreement with a Blue Cross Blue Shield (BCBS) health plan, marking a pivotal expansion in the fast-growing digital health landscape. This move integrates Dario's AI-driven cardiometabolic digital health solutions, covering diabetes, hypertension, and weight management, into the offerings of one of America's most trusted health insurers. According to a recent report, the card.
DarioHealth Announces New Blue Cross Blue Shield Agreement, Expanding Health Plan Client Base
DarioHealth expands its payer network with a new Blue Cross Blue Shield agreement, bolstering recurring revenue growth and reinforcing its position in one of healthcare's fastest-growing sectors; Dario's AI-driven digital health platform continues to drive adoption among payers seeking scalable, data-driven solutions NEW YORK , Feb. 6, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that it has secured a new agreement with a Blue Cross Blue Shield (BCBS) health plan, marking a significant expansion of its presence in the health plan market. The program, rolled out in January 2025, allows members seamless access to Dario's evidence-based, AI-driven health coaching and monitoring tools.
PESG Report: DarioHealth Positions Itself as a Market Leader in the Multi-Billion-Dollar Digital Health Transformation
NEW YORK--(BUSINESS WIRE)---- $DRIO #GLP1--PESG Releases Report: In a healthcare market brimming with potential, DarioHealth Corp. (Nasdaq: DRIO)* is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it seems DarioHealth's multi-condition digital health platform and its accelerating financial trajectory may position it as a sleeper hit in a rapidly growing sector. Breaking Down the Opportunity At the heart of DarioHealth's success is.
DarioHealth Announces $25.6M Private Placement Positioning the Company to Execute on Strategy Aiming to Reach Operational Cash Flow Positive Run Rate by the End of 2025
Significant participation from existing shareholders and accredited healthcare investors, which the company believes underscores confidence in its strategy Financing supports execution of long-term growth initiatives focused on high-margin, scalable recurring revenues across B2B (Business-to-Business) and pharma channels NEW YORK , Jan. 21, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a prominent leader in the global digital health industry, announced today the successful closing of a $25.6 million private placement of convertible preferred stock, priced in accordance with Nasdaq market rules. The majority of the funds were secured from existing shareholders, with the remainder contributed by a network of leading accredited healthcare investors and executives from the healthcare sector.
DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly Growing Multi Billion Dollar Market
NEW YORK--(BUSINESS WIRE)--Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The company's latest move expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical weight-loss solutions skyrockets across employers and consumers. Following the announcement, Dario's shar.
DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets
New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK , Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a collaboration with MediOrbis, a multi-specialty digital health provider, to add prescribing capabilities to Dario's GLP-1 behavior change solution for a comprehensive medical weight loss program. This strategic addition creates a fully integrated solution for employers covering weight-loss medications and supports direct-to-consumer offerings, expanding Dario's addressable market in one of the fastest-growing segments of digital health.
Dario Signs Four New Employer Contracts Across Full Product Suite
Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023 NEW YORK , Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025. Dario has added four new employer contracts to the 2025 book of business, continuing the business momentum in the Business-to-Business-to-Consumer (B2B2C) channel and securing recurring revenue from these accounts starting in the first quarter of 2025.
DarioHealth Corp. (DRIO) Q3 2024 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Third Quarter 2024 Results Call. [Operator Instructions] This call is being recorded on November 7, 2024.
Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement
The new platform services subscription contract with a top six U.S. pharma client marks a pivotal shift in Dario's pharma channel, transitioning the business model from milestone-based to recurring service subscription fees by expanding engagement with payors and pharmacy benefit managers (PBMs) NEW YORK , Nov. 4, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new collaboration with a pharma company that will utilize Dario Connect (formerly Twill Care) among their patient populations to further their direct-to-consumer efforts using Dario's refined engagement and navigation technologies. In an effort to strengthen and expand connections across patient populations that are candidates for a new drug to treat psoriasis, a top pharmaceutical company chose Dario to pilot a cutting-edge initiative aimed to help onboard patients that will engage with the drug via the platform.
Dario Signs New Regional Health Plan, Expanding Reach in Medicaid Population
The new contract marks the eighth health plan for Dario and will contribute to revenues starting immediately. NEW YORK , Oct. 30, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a regional health plan in the Medicaid space, which has launched with the full suite of cardiometabolic solutions.
DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th
Company to host conference call and webcast at 8:30am ET NEW YORK , Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.
Dario Announces Complete Integration of Twill Capabilities Across Full Multi-Condition Platform
Integration of behavioral health and wellbeing solutions with navigation and engagement technology creates the most comprehensive solution in the market under the Dario brand NEW YORK , Oct. 17, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, today announces the full integration of Twill's advanced behavioral health and navigation capabilities into the Dario platform. The integration completes Dario's effort to create one of the most comprehensive and effective end-to-end digital health solutions in the market.
Twill by Dario to Offer a Benefit for AARP Members
New offer gives Dario access to millions of AARP members, enabling engagement with people over 50 in health and well-being beginning in January 2025 NEW YORK , Oct. 15, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new AARP member benefit that provides members with proven digital behavioral health and well-being solutions from Twill by Dario. The new benefit is expected to launch in January of 2025 for AARP members.
National Medicare Health Plan Partners with Twill by Dario to Promote Healthy Aging with New Digital Mental Health Benefits for Seniors
The new contract significantly expands Dario's footprint with more than a million eligible members beginning January 2025 NEW YORK , Oct. 1, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national Medicare Advantage health plan (the "Plan") to launch its behavioral health solution for the Plan members beginning in January 2025. This new contract marks the beginning of a strategic relationship, starting with Dario's behavioral health solution, Twill by Dario, in 2025 and potentially expanding to additional Dario solutions in 2026 and beyond.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DRIO.